Evidence map›Paper›PMID 35462591›Full record

ArticleClinical oral investigations2022

Local delivery of a CXCR3 antagonist decreases the progression of bone resorption induced by LPS injection in a murine model.

Soma Lari, Sarah Hiyari, Davi Neto de Araújo Silva, Beatriz de Brito Bezerra, Makiko Ishii, Sepehr Monajemzadeh, Zhong-Kai Cui, Sotirios Tetradis, Min Lee, Flavia Q Pirih

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical oral investigations, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Journal of oral microbiology · 2026
    Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 4 countries.

Soma LariSchool of Dentistry, Section of Periodontics, University of California, Los Angeles, Los Angeles, Los Angeles, CA, USA.
Sarah HiyariSchool of Dentistry, Section of Periodontics, University of California, Los Angeles, Los Angeles, Los Angeles, CA, USA.
Davi Neto de Araújo SilvaSchool of Dentistry, Section of Periodontics, University of California, Los Angeles, Los Angeles, Los Angeles, CA, USA.
Beatriz de Brito BezerraSchool of Dentistry, Section of Periodontics, University of California, Los Angeles, Los Angeles, Los Angeles, CA, USA.
Makiko IshiiDivision of Periodontology, Department of Oral Biology and Tissue Engineering, Meikai University School of Dentistry, Urayasu, Japan.
Sepehr MonajemzadehSchool of Dentistry, Section of Periodontics, University of California, Los Angeles, Los Angeles, Los Angeles, CA, USA.
Zhong-Kai CuiDepartment of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
Sotirios TetradisSchool of Dentistry, Section of Oral Radiology, University of California, Los Angeles, Los Angeles, CA, USA.
Min LeeSchool of Dentistry, Section of Biomaterials Science, University of California, Los Angeles, Los Angeles, CA, USA.
Flavia Q PirihSchool of Dentistry, Section of Periodontics, University of California, Los Angeles, Los Angeles, Los Angeles, CA, USA. fpirih@dentistry.ucla.edu.ORCID http://orcid.org/0000-0003-1670-7345
University of California, Los Angeles · USMeikai University · JPSouthern Medical University · CN

Funding

Mouse Genome-Wide Association Studies in LPS-Induced Bone LossR21DE023901 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PIRIH, FLAVIA · 2014 to 2015
$407k
NIDCR NIH HHS DE023901-01NIDCR NIH HHS R21 DE023901
6 · The paper itself

Abstract

objectivesThis experimental study was carried out to investigate the effects of locally delivered nanoparticles (AMG-487 NP) containing a CXCR3 antagonist in inhibiting the progression of LPS-induced inflammation, osteoclastic activity, and bone resorption on a murine model. MATERIALS AND

methodsThirty, 7-week-old C57BL/6 J male mice were used. Inflammatory bone loss was induced by Porphyromonas gingivalis-lipopolysaccharide (P.g.-LPS) injections between the first and second maxillary molars, bilaterally, twice a week for 6 weeks (n = 20). AMG-487 NP were incorporated into a liposome carrier and locally delivered on sites where P.g.-LPS was injected. Control mice (n = 10) were injected with vehicle only. Experimental groups included (1) control, (2) LPS, and (3) LPS + NP. At the end of 1 and 6 weeks, mice were euthanized, maxillae harvested, fixed, and stored for further analysis.

resultsVolumetric bone loss analysis revealed, at 1 week, an increase in bone loss in the LPS group (47.9%) compared to control (27.4%) and LPS + NP (27.8%) groups. H&E staining demonstrated reduced inflammatory infiltrate in the LPS + NP group compared to LPS group. At 6 weeks, volumetric bone loss increased in all groups; however, treatment with the CXCR3 antagonist (LPS + NP) significantly reduced bone loss compared to the LPS group. CXCR3 antagonist treatment significantly reduced osteoclast numbers when compared to LPS group at 1 and 6 weeks.

conclusionsThis study showed that local delivery of a CXCR antagonist, via nanoparticles, in a bone resorption model, induced by LPS injection, was effective in reducing inflammation, osteoclast numbers, and bone loss. CLINICAL RELEVANCE: CXCR3 blockade can be regarded as a novel target for therapeutic intervention of bone loss. It can be a safe and convenient method for periodontitis treatment or prevention applicable in clinical practice.

Indexed as

Alveolar Bone LossBone ResorptionAnimalsDisease Models, AnimalInflammationLipopolysaccharidesMaleMiceMice, Inbred C57BLOsteoclastsPorphyromonas gingivalisLipopolysaccharidesAMG-487 nanoparticlesBone resorptionCXCR3 antagonistInflammatory infiltrateOsteoclast

Identifiers

PMID35462591
PMCPMC9710470
OpenAlexW4224312192

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.